Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Siskind

Showing results (241-250 of 292) with videos related to

Pageof 30
Sort By:
The Lancet. Psychiatry|November 5, 2025
Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychoticsJurjen J Luykx, Mark Colgan, Eduard Vieta, et al.
BMJ Open|March 4, 2018
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapineDan Siskind, Nadia Friend, Anthony Russell, et al.
General Hospital Psychiatry|March 31, 2022
Assessing dietary, exercise, and non-pharmacological modalities within psychiatric hospitalsNajwa-Joelle Metri, Carolyn Ee, Jon Wardle, et al.
Expert Opinion on Drug Safety|November 27, 2019
The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacyKenya A Costa-Dookhan, Sri Mahavir Agarwal, Araba Chintoh, et al.
Therapeutic Advances in Psychopharmacology|October 21, 2021
CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapineDan Siskind, Anthony W Russell, Shuichi Suetani, et al.
Therapeutic Advances in Psychopharmacology|April 28, 2023
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case seriesFemin Prasad, Riddhita De, Vittal Korann, et al.
The Australian and New Zealand Journal of Psychiatry|November 11, 2025
The feasibility of resistance training versus aerobic exercise in a rehabilitation setting for people living with psychotic disorders: A randomised controlled trialNicole Korman, Robert Stanton, Mike Trott, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2022
The role of metformin as a treatment for neuropsychiatric illnessSeetal Dodd, Luba Sominsky, Dan Siskind, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|December 16, 2014
Getting started in research: systematic reviews and meta-analysesStephen Kisely, Alice Chang, Jim Crowe, et al.
Bjpsych Open|July 22, 2025
Schizophrenia, Nutrition and Choices in Kilojoules (SNaCK): protocol for a feasibility and acceptability randomised controlled trial of two dietary interventionsDonni Johnston, Urska Arnautovska, Andrea Baker, et al.
Pageof 30

Showing results (241-250 of 292) with videos related to

Sort By:
Pageof 30
The Lancet. Psychiatry|November 5, 2025
Transdiagnostic effectiveness and safety of clozapine in individuals with psychotic, affective, and personality disorders: nationwide and meta-analytic comparisons with other antipsychoticsJurjen J Luykx, Mark Colgan, Eduard Vieta, et al.
BMJ Open|March 4, 2018
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapineDan Siskind, Nadia Friend, Anthony Russell, et al.
General Hospital Psychiatry|March 31, 2022
Assessing dietary, exercise, and non-pharmacological modalities within psychiatric hospitalsNajwa-Joelle Metri, Carolyn Ee, Jon Wardle, et al.
Expert Opinion on Drug Safety|November 27, 2019
The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacyKenya A Costa-Dookhan, Sri Mahavir Agarwal, Araba Chintoh, et al.
Therapeutic Advances in Psychopharmacology|October 21, 2021
CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapineDan Siskind, Anthony W Russell, Shuichi Suetani, et al.
Therapeutic Advances in Psychopharmacology|April 28, 2023
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case seriesFemin Prasad, Riddhita De, Vittal Korann, et al.
The Australian and New Zealand Journal of Psychiatry|November 11, 2025
The feasibility of resistance training versus aerobic exercise in a rehabilitation setting for people living with psychotic disorders: A randomised controlled trialNicole Korman, Robert Stanton, Mike Trott, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 3, 2022
The role of metformin as a treatment for neuropsychiatric illnessSeetal Dodd, Luba Sominsky, Dan Siskind, et al.
Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|December 16, 2014
Getting started in research: systematic reviews and meta-analysesStephen Kisely, Alice Chang, Jim Crowe, et al.
Bjpsych Open|July 22, 2025
Schizophrenia, Nutrition and Choices in Kilojoules (SNaCK): protocol for a feasibility and acceptability randomised controlled trial of two dietary interventionsDonni Johnston, Urska Arnautovska, Andrea Baker, et al.
Pageof 30